DEMO WHEAT ZOOMER 09/25/2011

PATIENT

NAME: **DEMO WHEAT ZOOMER** GENDER: **Male**DATE OF BIRTH: **09/25/2011** AGE: **9**

ACCESSION ID: 2109220473

SPECIMEN COLLECTION TIME: 09-21-2021 12:14 SPECIMEN RECEIVED TIME: 09-22-2021 06:15 FINAL REPORT TIME: 09-22-2021 12:16

FASTING: FASTING

PROVIDER

PRACTICE NAME: Vibrant IT4 Practice
PROVIDER NAME: Demo Client, DDD (999994)
ADDRESS: TEST STREET, TEST CITY, KY- 42437.

The comments in this report are meant only for informational purposes and do not constitute medical advice. Please consult your physician for any medication, treatment or life style management.

Vibrant America Test Index



Food Summary 🐔

PATIENT

NAME: DEMO WHEAT ZOOMER GENDER: Male

DATE OF BIRTH: 09/25/2011 AGE: 9

ACCESSION ID: 2109220473

SPECIMEN COLLECTION TIME: 09-21-2021 12:14 SPECIMEN RECEIVED TIME: 09-22-2021 06:15 FINAL REPORT TIME: 09-22-2021 12:16

FASTING: FASTING

PROVIDER

PRACTICE NAME: Vibrant IT4 Practice PROVIDER NAME: Demo Client, DDD (999994) ADDRESS: TEST STREET, TEST CITY, KY- 42437.























Food	Food Summary Blank Cell - Low Reactivity						● High Reactivity ● Moderate Reactivity Not Ordered or N/A					rdered or N/A		
•	Food Name	lgA	IgG	IgE	lgG4	C3D	Peptide level sensitivity	Food Name	lgA	lgG	lgE	lgG4	C3D	Peptide level sensitivity
Foods	Intestinal Perm.	-	-	-	-	-		Wheat	-	-	-	-	-	•
High Reactivity F														



















Risk and Limitations

This test has been developed and its performance characteristics determined by Vibrant America LLC., a CLIA certified lab. These assays have not been cleared or approved by the U.S. Food and Drug Administration.

Allergen-specific IgE assays do not demonstrate absolute positive and negative predictive values for allergic disease. Clinical history must be incorporated into the diagnostic determination. Quantification of specific IgG and IgA antibodies is not FDA-recognized diagnostic indicator of allergy.

Food allergen, Inhalant, Food additives, Food Sensitivity and Food Zoomers testing is performed at Vibrant America, а CLIA certified laboratory and utilizes ISO-13485 developed technology. Vibrant effective America has procedures in protect against technical and operational problems. However, such may still occur. Examples include failure to obtain the result for a specific antigen due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

The information in this report is intended for educational purposes only. While every attempt has been made to provide current and accurate information, neither the author nor the publisher can be held accountable for any errors or omissions.

Vibrant Wellness makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant Wellness reports and other information do not constitute medical advice and are not a substitute for professional medical advice. Please consult your healthcare practitioner for questions regarding test results, or before beginning any course of supplementation or dietary changes.

PATIENT

NAME: **DEMO WHEAT ZOOMER** GENDER: **Male**DATE OF BIRTH: **09/25/2011** AGE: **9**

ACCESSION ID: 2109220473

SPECIMEN COLLECTION TIME: 09-21-2021 12:14 SPECIMEN RECEIVED TIME: 09-22-2021 06:15 FINAL REPORT TIME: 09-22-2021 12:16

FASTING: FASTING

PROVIDER

PRACTICE NAME: Vibrant IT4 Practice
PROVIDER NAME: Demo Client, DDD (999994)
ADDRESS: TEST STREET, TEST CITY, KY- 42437.

The comments in this report are meant only for informational purposes and do not constitute medical advice. Please consult your physician for any medication, treatment or life style management.

Vibrant Wellness Test Index





Final Report Date: 09-22-2021 12:16 Specimen Collected: 09-21-2021 12:14

Accession ID: 2109220473 Specimen Received: 09-22-2021 06:15

LAST NAME FIRST NAME GENDER DATE OF BIRTH ACCESSION ID DATE OF SERVICE
WHEAT ZOOMER DEMO MALE 2011-09-25 2109220473 09-21-2021 12:14

PATIENT

Name: DEMO WHEAT ZOOMER

Date of Birth: 2011-09-25 Gender: Male

Gender: Age: 9

Fasting: FASTING

PROVIDER

Practice Name: Vibrant IT4 Practice

Provider Name: Demo Client, DDD (999994)

Street Address: TEST STREET

City: TEST CITY State: KY Zip #: 42437 Telephone #:

Fax #: 000-000-0000

Vibrant Wellness is pleased to present to you, **WheatZoomer** testing, to help you make healthy lifestyle and dietary choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being.

The Vibrant Wheat Zoomer is a wheat sensitivity analytics tool consisting of a microarray platform of wheat antigens which offers very specific antibody-to-antigen recognition. The panel is designed to assess an individual's IgG and IgA sensitivity to these antigens at the peptide level. Additionally, the panel tests for the HLA isoforms associated with celiac disease and wheat allergy testing is performed by checking for IgE antibodies against wheat.

Interpretation of Report: The summary score provided for Wheat Zoomer is a unified score calculated from the IgE, IgA and IgG reactivity of the individual to the respective antigens with higher weightage for IgE than IgA than IgG. Weightage is also assigned to the antigens based on its importance and abundance in the specific food that is tested. The intestinal permeability score is a unified score calculated from the serum zonulin result and antibody reactivity to the antigens in the Intestinal Permeability panel (anti-zonulin IgA, anti-actin IgA, ant


In the detailed report, the test results of antibody levels to the individual proteins are calculated by comparing the average intensity of the individual protein antibody to that of a healthy reference population. Reference ranges have been established for pediatric and adult population using 192 healthy individuals. The results are displayed as High Risk, Moderate or In Control. A High Risk (Red) result indicates that you have an increased reactivity to the antigen with respect to the reference range. A Moderate (Yellow) sensitive result indicates that you have a moderate reactivity to the food antigen with respect to the reference range. A Negative or In Control (Green) result indicates that you have a low reactivity to the food antigen with respect to the reference range. Vibrant utilizes proprietary fluorescent analysis which is designed to assay specific total IgG (subclasses 1, 2, 3, 4) and total IgA (subclasses 1, 2) antibodies. The classification of High Risk to Moderate to In Control denotes the level of antibody reactivity detected through this analysis.

Ratings for the references are calculated based on the Impact Factor, Citations, and Study Population of the references which correlate the antigen/antibody with the associated conditions. It is indicated based on a star based system (1 star – 5 stars) with 5 stars indicating the best correlation of the protein with the potential associated risk. The Impact Factor of the journal in which the reference is published is the number of citations received by articles published in that journal during the two preceding years, divided by the total number of articles published in that journal during the two preceding years. Study population includes the number of samples tested along with gender, age and ethnicity of the population.

The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. Testing for Wheat Zoomer panel is performed by Vibrant America, a CLIA certified lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to accept these terms, you shall not access, browse, or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your physician/dietitian for medication, treatment, or lifestyle management. This product is not intended to diagnose, treat, or cure any disease.

Please Note - It is important that you discuss any modifications to your diet, exercise and nutritional supplementation with your physician before making any changes.





	Positive	Mod	lerate
IgG	IgA	IgG	IgA
Intestinal Permeability Panel Anti-Zonulin Anti-Actin Transglutaminase Panel Transglutaminase 3 Transglutaminase 6 Wheat Germ Panel Wheat Germ Agglutinin Gliadin Panel Alpha Gliadin Alpha-Beta Gliadin Gamma Gliadin Omega Gliadin Gluteomorphin Prodynorphin Glutenin Panel LMW Glutenin Non-Gluten Wheat Panel Serpin Farinins	Intestinal Permeability Panel Anti-LPS Transglutaminase Panel Transglutaminase 3 Wheat Germ Panel Wheat Germ Agglutinin Gliadin Panel Alpha Gliadin Alpha-Beta Gliadin Gamma Gliadin Gmega Gliadin Gluteomorphin Prodynorphin Prodynorphin Glutenin Panel LMW Glutenin Non-Gluten Wheat Panel Serpin		Non-Gluten Wheat Panel Farinins Amylase/Protease Inhibitors Globulins Purinin
Amylase/Protease Inhibitors Globulins Purinin	Neg	ative	
	Celiac		inase 2, DGP
tTG/I	DGP Complex	_	usion Peptide
	utenin Panel		Glutenin

Wheat Allergy Pa	Wheat Allergy Panel												
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous						
Wheat Allergen IgE (kU/L)	<0.10			≤0.34	0.35~3.49	≥3.50	<0.10 08/22/2021						



Other							
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Zonulin (ng/mL)			81.5	≤45.3	45.4~55.3	≥55.4	<10.0 08/22/2021







Celiac							
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Transglutaminase 2 IgG	0.60			≤0.94	0.95~1.05	≥1.06	0.46 08/22/2021
Transglutaminase 2 IgA	0.38			≤0.94	0.95~1.05	≥1.06	2.80 08/22/2021
DGP IgG	0.25			≤0.94	0.95~1.05	≥1.06	2.00 08/22/2021
DGP IgA	0.18			≤0.94	0.95~1.05	≥1.06	1.20 08/22/2021

tTG/DGP Complex	C						
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
tTG/DGP Fusion Peptide IgG	0.30			≤0.89	0.90~1.10	≥1.11	0.16 08/22/2021
tTG/DGP Fusion Peptide IgA	0.20			≤0.89	0.90~1.10	≥1.11	0.85 08/22/2021

Intestinal Permeab	ility Panel						
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Zonulin (ng/mL)			81.5	≤45.3	45.4~55.3	≥55.4	<10.0 08/22/2021
Anti-Zonulin IgG			1.14	≤0.89	0.90~1.10	≥1.11	0.77 08/22/2021
Anti-Zonulin IgA	0.60			≤0.89	0.90~1.10	≥1.11	0.20 08/22/2021
Anti-Actin IgG			1.52	≤0.89	0.90~1.10	≥1.11	0.67 08/22/2021
Anti-Actin IgA	0.74			≤0.89	0.90~1.10	≥1.11	0.09 08/22/2021
Anti-LPS IgA (U/ml)			60.0	≤30.0		≥30.1	61.0 08/22/2021
Anti-LPS (IgG + IgM) (U/ml)	89.0			≤281.0		≥281.1	86.0 08/22/2021



Transglutaminase	Panel						
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Transglutaminase 3 IgG			1.53	≤0.79	0.80~1.00	≥1.01	0.63 08/22/2021
Transglutaminase 3 IgA			1.02	≤0.79	0.80~1.00	≥1.01	0.42 08/22/2021
Transglutaminase 6 lgG			1.15	≤0.79	0.80~1.00	≥1.01	0.29 08/22/2021
Transglutaminase 6 lgA	0.66			≤0.79	0.80~1.00	≥1.01	0.23 08/22/2021

Wheat Germ Panel							
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Wheat Germ Agglutinin IgG			1.32	≤0.79	0.80~1.00	≥1.01	0.57 08/22/2021
Wheat Germ Agglutinin IgA			1.02	≤0.79	0.80~1.00	≥1.01	0.21 08/22/2021





Gliadin Panel							
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Alpha Gliadin IgG			1.72	≤0.79	0.80~1.00	≥1.01	0.79 08/22/2021
Alpha Gliadin IgA			1.27	≤0.79	0.80~1.00	≥1.01	0.39 08/22/2021
Alpha-Beta Gliadin IgG			1.32	≤0.79	0.80~1.00	≥1.01	0.40 08/22/2021
Alpha-Beta Gliadin IgA			1.02	≤0.79	0.80~1.00	≥1.01	0.97 08/22/2021
Gamma Gliadin IgG			1.67	≤0.79	0.80~1.00	≥1.01	0.41 08/22/2021
Gamma Gliadin IgA			1.42	≤0.79	0.80~1.00	≥1.01	0.34 08/22/2021
Omega Gliadin IgG			1.30	≤0.79	0.80~1.00	≥1.01	0.06 08/22/2021
Omega Gliadin IgA			1.07	≤0.79	0.80~1.00	≥1.01	0.62 08/22/2021
Gluteomorphin IgG			1.43	≤0.79	0.80~1.00	≥1.01	0.77 08/22/2021
Gluteomorphin IgA			1.09	≤0.79	0.80~1.00	≥1.01	0.43 08/22/2021
Prodynorphin IgG			1.48	≤0.79	0.80~1.00	≥1.01	0.12 08/22/2021
Prodynorphin IgA			1.17	≤0.79	0.80~1.00	≥1.01	0.02 08/22/2021

Glutenin Panel							
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
HMW Glutenin IgG	0.68			≤0.79	0.80~1.00	≥1.01	0.90 08/22/2021
HMW Glutenin IgA	0.69			≤0.79	0.80~1.00	≥1.01	0.25 08/22/2021
LMW Glutenin IgG			1.50	≤0.79	0.80~1.00	≥1.01	0.32 08/22/2021
LMW Glutenin IgA			1.15	≤0.79	0.80~1.00	≥1.01	0.86 08/22/2021



Non-Gluten Wheat	Panel						
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Serpin IgG			1.30	≤0.79	0.80~1.00	≥1.01	0.87 08/22/2021
Serpin IgA			1.02	≤0.79	0.80~1.00	≥1.01	0.36 08/22/2021
Farinins IgG			1.23	≤0.79	0.80~1.00	≥1.01	0.18 08/22/2021
Farinins IgA		0.93		≤0.79	0.80~1.00	≥1.01	0.37 08/22/2021
Amylase/Protease Inhibitors IgG			1.25	≤0.79	0.80~1.00	≥1.01	0.01 08/22/2021
Amylase/Protease Inhibitors IgA		0.94		≤0.79	0.80~1.00	≥1.01	0.99 08/22/2021
Globulins IgG			1.30	≤0.79	0.80~1.00	≥1.01	0.58 08/22/2021
Globulins IgA		0.98		≤0.79	0.80~1.00	≥1.01	0.48 08/22/2021
Purinin IgG			1.40	≤0.79	0.80~1.00	≥1.01	0.96 08/22/2021
Purinin IgA		1.00		≤0.79	0.80~1.00	≥1.01	0.87 08/22/2021





Intestinal Permeability Panel

Intestinal Permeability Panel

Potential Risk:

Antibodies to actin suggest leaky gut diagnosis.;

Increased levels of zonulin/anti-zonulin antibodies indicate leaky gut condition;

Increased levels of lipopolysaccharides antibodies indicate leaky gut condition.

Related Information:

Actin is responsible for regulating paracellular flow across the intestinal epithelium. However, increased levels of actin suggest epithelial cell damage leading to increased intestinal permeability and decreased barrier function.;

High levels of lipopolysaccharides (LPS) antibodies are indicative of penetration of LPS into the bloodstream. LPS binds to cells lining the gut and increases synthesis of pro-inflammatory substances.;

Zonulin acts as the gate-keeper between the cells of the intestinal lining in order for nutrients and other essential molecules to be transported in and out of the intestine. However, when leaky gut is present, the intestinal lining is compromised allowing larger protein molecules to get into the bloodstream thereby causing an immune response.

Potential Risk Mitigation Choices:

Consider subsequent testing of your gut bacteria profile to identify an optimum dosage of the right probiotic necessary to help fix your leaky gut. A combination therapy may be recommended using probiotics, L-glutamine, L-arginine and Omega3 supplementation.







Transglutaminase Panel

Transglutaminase Panel

Potential Risk:

Antibodies to TG3 is associated with skin related conditions like dermatitis herpetiformis and is known to be associated with gluten triggered immune outbreaks.;

Antibodies to TG6 is associated with gluten triggered neurological destruction and can lead to gluten alaxia.

Related Information:

Ataxia is a lack of muscle coordination which may affect speech, eye movements, the ability to swallow, walking, picking up objects and other voluntary movements.;

Transglutaminases are enzymes found within the body and immune reactions to transglutaminase indicates the presence of an autoimmune condition.

Potential Risk Mitigation Choices:

Consider being on a strict gluten free diet.







Wheat Germ Panel

Wheat Germ Panel

Potential Risk:

Increased antibody titers to WGA suggests a leaky gut condition and may explain the cause of Vitamin D deficiency.

Related Information:

Wheat Germ Agglutinin (WGA) binds to N-glycolylneuraminic acid (Neu5Ac), the sialic acid predominantly found in humans, allowing it to adhere to cell surfaces like the epithelial layer of the gut. WGA irritates and causes premature cell death in the gut and has been known to lead to a leaky gut condition.

Potential Risk Mitigation Choices:

Consider subsequent testing of your gut bacteria profile to identify an optimum dosage of the right probiotic necessary to help fix your leaky gut. A combination therapy may be recommended using probiotics, L-glutamine, L-arginine and Omega3 supplementation.







Gliadin Panel

Gliadin Panel

Potential Risk:

Increased levels of Beta Gliadin IgG/IgA could suggest sensitivity to the beta gliadin component of gluten.;

Antibodies to prodynorphin have been found to be elevated in individuals with gluten sensitivity associated neurochemical disorders.:

Increased levels of Gamma Gliadin IgG/IgA could suggest sensitivity to the gamma gliadin component of gluten.;

Antibodies to gluteomorphin have been found to be elevated in individuals with gluten sensitivity associated neurochemical disorders.;

Increased levels of Omega Gliadin IgG/IgA could suggest sensitivity to the omega gliadin component of gluten.;

Increased levels of Alpha Gliadin IgG/IgA could suggest sensitivity to the alpha gliadin component of gluten.

Related Information:

Gliadin constitutes a class of proteins that are present in wheat and other cereal which give it the ability to rise properly when baked. The main types of gliadin are alpha, beta, gamma and omega gliadins. Research has suggested that antibody reactivity against all the above mentioned forms of gliadin are found in individuals with 'Wheat related disorders.';

If a person has elevated antibodies to Gluteomorphin or Prodynorphin, they may have severe neurochemical reactions to gluten and also create what is called a gluteomorphin withdrawal response. This is a response that causes a patient to have significant reactions such as depression, mood swings, abnormal bowel activity when they go on a gluten-free diet. If this occurs the person must hang in there for a couple of weeks being gluten-free to potentially avoid harmful disorders.

Potential Risk Mitigation Choices:

Consider avoiding wheat in your diet.;

Consider going on a gluten free diet.





Glutenin Panel

Glutenin Panel

Potential Risk:

Elevated levels of LMW Glutenin has been associated with Wheat Sensitivity, asthma, Atopic dermatitis, Urticaria and Anaphylaxis.

Potential Risk Mitigation Choices:

Consider avoiding wheat in your diet.







Non-Gluten Wheat Panel

Non-Gluten Wheat Panel

Potential Risk:

Increased levels of antibodies to non-gluten wheat proteins (serpins, purinins, farinins, amylase/protease inhibitors and globulins) are responsible for inflammation in patients with wheat sensitive enteropathies.

Related Information:

Non-gluten proteins constitute about 25% of the total protein content of wheat cereal. Recently it has been shown that these non-gluten proteins are immune-reactive in individuals with wheat sensitivity. The 5 groups of non-gluten proteins which are distinctly different from the gluten proteins that are responsible for inflammation in patients with wheat sensitivity are serpins, purinins, farinins, amylase/protease inhibitors and globulins.

Potential Risk Mitigation Choices:

Consider avoiding wheat in your diet.







Other

Other

Potential Risk:

Increased levels of zonulin/anti-zonulin antibodies indicate leaky gut condition

Related Information:

Zonulin acts as the gate-keeper between the cells of the intestinal lining in order for nutrients and other essential molecules to be transported in and out of the intestine. However, when leaky gut is present, the intestinal lining is compromised allowing larger protein molecules to get into the bloodstream thereby causing an immune response.

Potential Risk Mitigation Choices:

Consider subsequent testing of your gut bacteria profile to identify an optimum dosage of the right probiotic necessary to help fix your leaky gut. A combination therapy may be recommended using probiotics, L-glutamine, L-arginine and Omega3 supplementation.





What is Gluten?

Gluten is a name for a group of proteins found in wheat, rye, barley and triticale. It acts as a 'glue' to give grains their doughy texture and is also commonly used as a food additive or thickener.

How to Eliminate Gluten Step-by-Step

If you have been instructed to go on a gluten-free diet, you might feel overwhelmed with how exactly to eliminate gluten 100% from your diet. Follow these steps to make your transition as smooth as possible:

- Work with your Vibrant Registered Dietitian
 Nutritionist to develop a custom plan to replace gluten-containing foods you may already be consuming regularly.
- 2. Learn what foods naturally contain gluten
- Learn what foods commonly have gluten added to them
- Learn what foods might contain hidden sources of gluten
- 5. Learn to read labels to identify gluten-free foods (consider using a smartphone app)
- Learn practical strategies to avoid cross contamination

Tips for Dining Out

- Be prepared and research the menu online before you arrive
- Explain your gluten-free needs to your server
- Ask detailed questions about how your food will be prepared (Are separate utensils used? Are separate preparation surfaces used? Etc)
- A number of apps exist that identify restaurants that cater to gluten-free patrons

Additional Resources

Celiac Disease Foundation www.celiac.org

Beyond Celiac (National Foundation of Celiac Awareness)

www.beyondceliac.org

The Gluten Intolerance Group of North America www.gluten.org

Gluten vs. Wheat...What's the Difference?

Gluten is a protein that is found in wheat, rye and barley. Wheat is a cereal grain that contains both gluten and non-gluten proteins. Most gluten free foods are wheat free but some may contain traces of wheat proteins.

Foods that contain gluten or might contain gluten*	Foods that are naturally gluten free*
Wheat and wheat products (farina, kamut, semolina, spelt, baked goods such as bread, cakes, cookies, granola bars, pasta and other sweets)	Animal proteins: beef, chicken, pork, fish, shellfish and wild game; eggs, yogurt, kefir, cottage cheese, milk (cow or goat)
Rye products and beer or ale made from rye	All fresh fruits
Seasoning blends, sauce mixes, gravies and dressings	All fresh vegetables
Soups and marinades	Pure herbs or spices (basil, cumin, oregano, etc)
Barley products and beer or ale made from barley, malt products such as malt vinegar, malted milk, malt flavor	
Soy sauce and teriyaki sauce	Legumes (beans)
Energy bars, trail mix, wheatgrass, cereals, oats (unless they say certified gluten- free)	Oils: coconut oil, extra virgin olive oil, avocado oil
Breaded foods, meatballs, veggie burgers, deli meat, cold cuts, imitation crab	Nuts: almonds, walnuts, peanuts, cashews, pistachios, Brazil nuts
Prescription and over-the- counter medications and supplements	Stevia and dark chocolate (70% or more cocoa)
Cosmetic products and skincare products	Wine

*naturally gluten-free foods may have gluten-containing ingredients added to them during processing, therefore it is always recommended to read labels before consuming



Glossary

Farinins - The name "Farinins" was given for avenin-like proteins because they are slightly closer in primary structure to gamma-gliadins than to avenins

Gliadin constitutes a class of proteins that are present in wheat and other cereal which give it the ability to rise properly when baked. The main types of gliadin are alpha, gamma and omega gliadins. Most commercial ELISA plates focus only on the alpha/gamma gliadin component and its deamidated forms. Research has however shown that antibody reactivity against all the 3 main forms of gliadin are found in individuals with 'Wheat related disorders'. The Vibrant Wheat Zoomer covers all known gliadins from all the different wheat species in both native and deamidated form making it the most comprehensive test against gliadins. The Vibrant Wheat Zoomer also includes all the key gliadin motifs—33mer alpha gliadin, 26mer gamma gliadin, 17mer omega gliadin.

Globulins - Several types of Globulins are also detected among the flour proteins. Proteins termed globulin-1 or alpha-globulin are encoded at the highly conserved Glo-2 locus between the loci for the x- and y-type HMW-GS on chromosome 1.

Glutenin is a major protein found in wheat and constitutes about 47% of its protein content. Glutenin is responsible for the strength and elasticity of dough. The main types of glutenin are the LMW (low molecular weight) and the HMW (high molecular weight) glutenin. HMW glutenin has been associated with Celiac disease, asthma and Atopic dermatitis. LMW Glutenin has been associated with Celiac disease, asthma, Atopic dermatitis, Urticaria and Anaphylaxis.

Gluteomorphin is an opioid peptide that is formed during digestion of the gliadin component of the gluten protein.

Intestinal Permeability is a term describing the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall, into the rest of the body. One way in which intestinal permeability is modulated is via CXCR3 receptors in cells in the intestinal epithelium, which respond to zonulin. Gliadin (a glycoprotein present in wheat) activates zonulin signaling irrespective of the genetic expression of autoimmunity, leading to increased intestinal permeability to macromolecules. The cytoskeleton is also made up of proteins, which comprise a network of thin, overlapping fibers known as the actin-myosin network. This partnership between the actin-myosin network proteins controls the permeability of the tight junctions, and thus the intestinal barrier.

Lipopolysaccharides (LPS) are a naturally occurring endotoxin found in the gut, genitourinal, and respiratory tracts. A healthy mucosal layer with intact tight junctions prevents the paracellular translocation of LPS. The presence of LPS antibodies in the blood has been discovered to be clinically relevant when attempting to identify the degree of intestinal barrier permeability.

Non Gluten Wheat Proteins Gliadins and Glutenins comprise approximately 70 different proteins and constitute about 75% of the total protein content of wheat cereal. The key proteins identified to be immune-reactive include Serpins, farinins, globulins, and amylase/protease inhibitors.

Prodynorphin is an opioid that is a basic building block of endorphins.

Purinin proteins are legumin-like 12 S globulin storage proteins encoded at Tri-A1 and Tri-D1 on the short arms of chromosomes 1A and 1D. The native proteins exist as hetero-tetramers composed of long and short arms from two cleaved, disulfide-linked triticin precursors.

Serpins are serine protease inhibitors and the wheat serpins are suicide substrate inhibitors of chymotrypsin and cathepsin A that may serve to inactivate serine proteases of grain-boring insects.

Transglutaminases – 2, 3 and 6 Transglutaminases are enzymes that catalyze an isopeptide bond formation between a free amine group and the acyl group. The Vibrant Wheat Zoomer includes transglutaminases 2, 3 and 6 which are known to be associated with various disease conditions. **Tissue transglutaminase or transglutaminase 2** IgA and IgG profile is one of the most important tests in the diagnostics of celiac disease. tTG is a known autoantigen in celiac disease which has replaced the tissue level tests like antiendomysium antibody test. Clinically tTG has been determined to have a strong sensitivity (99%) and specificity (90%) for identifying celiac disease. While Wheat sensitivity in many cases presents itself as celiac disease in some individuals it is associated with dermatitis herpetiformis. Serum from patients with dermatitis herpetiformis has shown an increased binding towards **transglutaminase 3** or epidermal transglutaminase. Gluten sensitivity is sometimes also associated with neurological disorders. This condition also known as gluten ataxia occurs in around 10% of the patients with gluten sensitivity. These patients have been found to have developed antibodies against a different transglutaminase namely **transglutaminase 6**.

tTG/DGP Complex – tTG/DGP complex comprises of a synthesized peptide which contains a portion of the tTG region and a portion of the DGP region. Recent studies support the hypothesis that a necepitope may be formed in CD patients' sera under in vivo physiological conditions, by a covalent cross-link between tTG and deamidated gliadin peptides, and this neo-antigen may be specifically recognized by autoantibodies. The tTG/DGP complex could potentially indicate the healing status of celiac disease.

Wheat alpha-amylase and protease inhibitors are reported to be active against the amylases and proteases from insects such as grain-boring weevils. However, they also are sufficiently abundant to serve as storage proteins for the developing grain and are a source of essential amino acids such as Lys, Met and Cys for humans who consume wheat products.

Wheat Germ Agglutenin Wheat germ agglutinin is a lectin that protects wheat from bacteria, yeast and insects and is naturally found in all wheat varieties. The Vibrant Wheat Zoomer includes the different agglutinins from both T.aestivum and T.urartu varieties. Lectins have the capacity to bind to different cell types and are also resistant to digestive enzymes making them a possible candidate for immune-sensitivity. Wheat Germ Agglutinin (WGA) irritates and causes premature cell death in the gut and has been known to lead to a leaky gut condition. WGA also disrupts the mucus membrane in the gut, which can cause bacterial overgrowth and lead to a host of digestive issues like GERD and ulcers.



References

PANEL	REFERENCE/ABSTRACT	RATING
LEAKY GUT PANEL	Alessio Fasano.Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer. This review talks about the increased interest in the role of a "leaky gut" in the pathogenesis of several pathological conditions targeting both the intestine and extra intestinal organs.	****
	Silvia Pedreira et.al. Significance of smooth muscle/anti-actin autoantibodies in celiac disease. The study evaluates the clinical relevance of the presence of IgA type anti-actin antibody (AAA) and SMA in 92 adult patient with celiac disease. The results indicted the presence of increased IgA AAA serum levels is a highly sensitive marker of the disturbed architecture of intestinal epithelial cells of CD patients also the presence of SMA seems to define a distinct subset of CD patients with a more severe clinical outcome.	***
	Melanie Uhde, Mary et. al. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. The study aims to determine if sensitivity to wheat in the absence of coeliac disease is associated with systemic immune activation that may be linked to an enteropathy.	****
WHEAT GERM PANEL	Karin de Punder and Leo Pruimboom. The Dietary Intake of Wheat and other Cereal Grains and Their Role in Inflammation. This review states the evidence from in vitro, in vivo and human intervention studies that describe how the consumption of wheat, other cereal grains, can contribute to the manifestation of chronic inflammation and autoimmune diseases by increasing intestinal permeability and initiating a pro-inflammatory immune response.	***
	L M Sollid, J Kolberg, H Scott, J Ek, O Fausa, and P Brandtzaeg. Antibodies to wheat germ agglutinin in coeliac disease. The study shows the celiac patients have significantly higher Serum IgG and IgA antibodies to wheat germ agglutinin (WGA) compared to the control group. Thus adding WGA as a potential biomarker for pathogenesis of CD.	**
	Alessio Fasano.Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation Autoimmunity, and Cancer. This review talks about the increased interest in the role of a "leaky gut" in the pathogenesis of several pathological conditions targeting be the intestine and extra intestinal organs.	****
GLIADIN PANEL	Luca Elli, Federica Branchi, Carolina Tomba, Danilo Villalta, Lorenzo Norsa, Francesca Ferretti, Leda Roncoroni, and Maria Teresa Bardella. Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity. The review article covers a complete overview of celiac disease, wheat allergy and non-celiac gluten sensitivity and its current clinical diagnosis.	**
	Chirdo FG, Rumbo M, Carabajal P, Mavromatópulos E, Castagnino N, Añón MC, Fossati CA. Determination of antigliadin antibodies in serologic tests for coeliac disease. The study compromised of 105 coeliac patients, 81 healthy controls, and 73 subjects in a disease control group to evaluate the efficacy of omega-gliadins to be a useful antigen in serologic detection of coeliac disease.	***
	Aristo Vojdani .The Characterization of the Repertoire of Wheat Antigens and Peptides Involved in the Humoral Immune Responses in Patients with Gluten Sensitivity and Crohn's Disease. The study examines the humoral immune response to various wheat proteins and peptides in patients with gluten sensitivity or Crohn's disease. In gluten-sensitive patients, IgG reacted most against transglutaminase, prodynorphin, wheat extract, and -, -, and -gliadin; IgA reacted most against wheat then transglutaminase, glutenin, and other peptides. In Crohn's disease patients, IgG reacted most against wheat and wheat germ agglutinin then transglutaminase, prodynorphin, -, and -gliadin; IgA reacted foremost against prodynorphin then transglutaminase and -gliadin.	**
This review deals with the current diagnosis and immunomodulatory treatments, as well as the role of whe enhance management and knowledge of Baker's Astma. Frances M Dupont et.al. Deciphering the complexities of the wheat flour proteome us dimensional electrophoresis, three proteases and tandem mass spectrometry.	G Salcedo, S Quirce, A Diaz-Perales. Wheat Allergens Associated with Baker's Asthma. This review deals with the current diagnosis and immunomodulatory treatments, as well as the role of wheat allergens as molecular tools to enhance management and knowledge of Baker's Astma.	***
	The study of wheat genome to identify the majority of abundant flour proteins for a single wheat cultivar, relate them to individual gene	***
NON GLUTEN WHEAT PANEL	Sina Huebener et. al. Specific Nongluten Proteins of Wheat are Novel Target Antigens in Celiac Disease Humoral Response. The study aims to investigate the level and molecular specificity of antibody response to wheat non gluten proteins in celiac disease. The results demonstrate that, in addition to the well-recognized immune reaction to gluten, celiac disease is associated with a robust humoral response directed at a specific subset of the no gluten proteins of wheat.	***
	Timo Reunala, Teea T. Salmi and Kaisa Hervonen. Dermatitis Herpetiformis: Pathognomonic Transglutaminase IgA Deposits in the Skin and Excellent Prognosis on a Gluten-free Diet. The study shows the coeliac disease in the gut appears to be a result of the IgA Epidermal transglutaminase antibody complexes aggregated into DH skin.	**
TRANSGLUTAMINASE PANEL	Hull CM, Liddle M, Hansen N, Meyer LJ, Schmidt L, Taylor T, Jaskowski TD, Hill HR, Zone JJ. Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. The study to determine the association between Dermatitis herpetiformis with IgA antibodies against TG2 and TG3. The results indicates IgA antibodies to TG3 are elevated in patients with DH and adults with Celiac disease.	***
	Gadoth A, Nefussy B, Bleiberg M, Klein T, Artman I, Drory VE. Transglutaminase 6 Antibodies in the Serum of Patients with Amyotrophic Lateral Sclerosis. The Study to evaluate the prevalence of celiac disease-related antibodies and HLA antigen alleles, as well as TG6 antibodies, in patients with amyotrophic lateral sclerosis (ALS) and healthy individuals serving as controls to determine whether a neurologic presentation of a gluten-related disorder mimicking ALS might occur in some patients. The result indicates certain cases, an ALS syndrome might be associated with autoimmunity and gluten sensitivity and also study indicates gluten sensitivity is potentially treatable with strict gluten free diet.	****
tTG/DGP Complex Panel	Margherita Di Pisa et.al. Synthetic Peptides Reproducing Tissue TransglutaminaseGliadin Complex Neo- epitopes as Probes for Antibody Detection in Celiac Disease Patients' Sera. Sera from 48 CD patients were collected at the diagnosis before gluten-free diet (39 females, 9 males; age range 2.252 years). Two of 48 (4%) CD patients presented IgA deficiency. Analysis of patients' subgroups established a possible clinical correlation not detected by established tests. These observations indicate that a neoepitope may be formed in CD patients' sera under in vivo physiological conditions, by a covalent cross-link between tTG and deamidated gliadin peptides, and this neo-antigen may be specifically recognized by autoantibodies.	***



Test Risk and Limitations

Wheat Zoomer testing is performed at Vibrant America, a CLIA certified laboratory, and utilizes ISO-13485 developed technology. However, laboratory error can occur, which might lead to incorrect results. Some of them may include sample mislabeling or contamination, operational error or failure to obtain data for certain proteins. Vibrant's laboratory may need a second sample to complete the testing.

Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific protein due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

Tested individuals should not change their diet, physical activity, or any medical treatments they are currently using based on genetic testing results without consulting their personal health care provider. These risk factors for Wheat Zoomer are based on selected peer reviewed scientific research findings as listed under references.

Tested individuals may find their experience is not consistent with Vibrant's selected peer reviewed scientific research findings of relative improvement for study groups. The science in this area is still developing and many personal health factors affect diet and health. Since subjects in the scientific studies referenced in this report may have had personal health and other factors different from those of tested individuals, results from these studies may not be representative of the results experienced by tested individuals. Further, some recommendations may or may not be attainable, depending on the tested individuals' physical ability or other personal health factors.

A limitation of this testing is that most scientific studies have been performed in Caucasian populations only. The interpretations and recommendations are done in the context of Caucasian studies, but the results may or may not be relevant to tested individuals of different or mixed ethnicities. Interference studies have not been established for individuals on immunosuppressive drugs.

Based on test results and other medical knowledge of the tested individual, health care providers might consider additional independent testing, or consult another health care provider or genetic counselor.